Tuesday, July 21, 2009 8:29:44 AM
A more obvious and egregious breach of fiduciary duty was Mr. Lanzafame's extraordinary move to sell the Myotech CSS technology at a knock down price to his own shell company set up by him with his pal Frank Terrizzi.
I can only think Mr. Lanzafame didn't realise that a DNS search of MyoCardioCare (thank you b9molecule) would reveal that he was the founder.
It was also interesting that the contract appended to the SEC filing had Lanzafame's signature as BIPH's CEO, but Terrizzi's signature as MyoCardioCare's President.
They must think Biophan shareholders are an extraordinarily naive and gullible group (!).
That said this is certainly an actionable breach of both fiduciary duty but also of securities legislation. Not the first by this bunch, and probably not the last, but perhaps the one which will break the camel's back?
For the sake of justice and good order in the financial markets, let's hope so.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM